Optical malignancy parameters for monitoring progression of breast cancer neoadjuvant chemotherapy

David R. Busch, Regine Choe, Mark A. Rosen, Wensheng Guo, Turgut Durduran, Michael D. Feldman, Carolyn Mies, Brian J. Czerniecki, Julia Tchou, Angela DeMichele, Mitchell D. Schnall, Arjun G. Yodh

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

We introduce and demonstrate use of a novel, diffuse optical tomography (DOT) based breast cancer signature for monitoring progression of neoadjuvant chemotherapy. This signature, called probability of malignancy, is obtained by statistical image analysis of total hemoglobin concentration, blood oxygen saturation, and scattering coefficient distributions in the breast tomograms of a training-set population with biopsy-confirmed breast cancers. A pilot clinical investigation adapts this statistical image analysis approach for chemotherapy monitoring of three patients. Though preliminary, the study shows how to use the malignancy parameter for separating responders from partial-responders and demonstrates the potential utility of the methodology compared to traditional DOT quantification schemes.

Original languageEnglish (US)
Pages (from-to)105-121
Number of pages17
JournalBiomedical Optics Express
Volume4
Issue number1
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Optical Tomography
chemotherapy
progressions
breast
transponders
cancer
Breast Neoplasms
image analysis
Drug Therapy
Physiologic Monitoring
tomography
signatures
Neoplasms
Hemoglobins
Breast
scattering coefficients
hemoglobin
Oxygen
Biopsy
blood

ASJC Scopus subject areas

  • Biotechnology
  • Atomic and Molecular Physics, and Optics

Cite this

Optical malignancy parameters for monitoring progression of breast cancer neoadjuvant chemotherapy. / Busch, David R.; Choe, Regine; Rosen, Mark A.; Guo, Wensheng; Durduran, Turgut; Feldman, Michael D.; Mies, Carolyn; Czerniecki, Brian J.; Tchou, Julia; DeMichele, Angela; Schnall, Mitchell D.; Yodh, Arjun G.

In: Biomedical Optics Express, Vol. 4, No. 1, 01.01.2013, p. 105-121.

Research output: Contribution to journalArticle

Busch, DR, Choe, R, Rosen, MA, Guo, W, Durduran, T, Feldman, MD, Mies, C, Czerniecki, BJ, Tchou, J, DeMichele, A, Schnall, MD & Yodh, AG 2013, 'Optical malignancy parameters for monitoring progression of breast cancer neoadjuvant chemotherapy', Biomedical Optics Express, vol. 4, no. 1, pp. 105-121. https://doi.org/10.1364/BOE.4.000105
Busch, David R. ; Choe, Regine ; Rosen, Mark A. ; Guo, Wensheng ; Durduran, Turgut ; Feldman, Michael D. ; Mies, Carolyn ; Czerniecki, Brian J. ; Tchou, Julia ; DeMichele, Angela ; Schnall, Mitchell D. ; Yodh, Arjun G. / Optical malignancy parameters for monitoring progression of breast cancer neoadjuvant chemotherapy. In: Biomedical Optics Express. 2013 ; Vol. 4, No. 1. pp. 105-121.
@article{c9f84c8e175d4631a4d2e354766fca1d,
title = "Optical malignancy parameters for monitoring progression of breast cancer neoadjuvant chemotherapy",
abstract = "We introduce and demonstrate use of a novel, diffuse optical tomography (DOT) based breast cancer signature for monitoring progression of neoadjuvant chemotherapy. This signature, called probability of malignancy, is obtained by statistical image analysis of total hemoglobin concentration, blood oxygen saturation, and scattering coefficient distributions in the breast tomograms of a training-set population with biopsy-confirmed breast cancers. A pilot clinical investigation adapts this statistical image analysis approach for chemotherapy monitoring of three patients. Though preliminary, the study shows how to use the malignancy parameter for separating responders from partial-responders and demonstrates the potential utility of the methodology compared to traditional DOT quantification schemes.",
author = "Busch, {David R.} and Regine Choe and Rosen, {Mark A.} and Wensheng Guo and Turgut Durduran and Feldman, {Michael D.} and Carolyn Mies and Czerniecki, {Brian J.} and Julia Tchou and Angela DeMichele and Schnall, {Mitchell D.} and Yodh, {Arjun G.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1364/BOE.4.000105",
language = "English (US)",
volume = "4",
pages = "105--121",
journal = "Biomedical Optics Express",
issn = "2156-7085",
publisher = "The Optical Society",
number = "1",

}

TY - JOUR

T1 - Optical malignancy parameters for monitoring progression of breast cancer neoadjuvant chemotherapy

AU - Busch, David R.

AU - Choe, Regine

AU - Rosen, Mark A.

AU - Guo, Wensheng

AU - Durduran, Turgut

AU - Feldman, Michael D.

AU - Mies, Carolyn

AU - Czerniecki, Brian J.

AU - Tchou, Julia

AU - DeMichele, Angela

AU - Schnall, Mitchell D.

AU - Yodh, Arjun G.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - We introduce and demonstrate use of a novel, diffuse optical tomography (DOT) based breast cancer signature for monitoring progression of neoadjuvant chemotherapy. This signature, called probability of malignancy, is obtained by statistical image analysis of total hemoglobin concentration, blood oxygen saturation, and scattering coefficient distributions in the breast tomograms of a training-set population with biopsy-confirmed breast cancers. A pilot clinical investigation adapts this statistical image analysis approach for chemotherapy monitoring of three patients. Though preliminary, the study shows how to use the malignancy parameter for separating responders from partial-responders and demonstrates the potential utility of the methodology compared to traditional DOT quantification schemes.

AB - We introduce and demonstrate use of a novel, diffuse optical tomography (DOT) based breast cancer signature for monitoring progression of neoadjuvant chemotherapy. This signature, called probability of malignancy, is obtained by statistical image analysis of total hemoglobin concentration, blood oxygen saturation, and scattering coefficient distributions in the breast tomograms of a training-set population with biopsy-confirmed breast cancers. A pilot clinical investigation adapts this statistical image analysis approach for chemotherapy monitoring of three patients. Though preliminary, the study shows how to use the malignancy parameter for separating responders from partial-responders and demonstrates the potential utility of the methodology compared to traditional DOT quantification schemes.

UR - http://www.scopus.com/inward/record.url?scp=84871786865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871786865&partnerID=8YFLogxK

U2 - 10.1364/BOE.4.000105

DO - 10.1364/BOE.4.000105

M3 - Article

C2 - 23304651

AN - SCOPUS:84871786865

VL - 4

SP - 105

EP - 121

JO - Biomedical Optics Express

JF - Biomedical Optics Express

SN - 2156-7085

IS - 1

ER -